eli lilly lepodisiran - Search News

Order byBest matchMost fresh

Eli Lilly, Risk Factor and Heart Disease

Seeking Alpha on MSN · 3d

Eli Lilly’s lepodisiran slashes inherited heart disease risk factor by 94% in Phase 2 trial

Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on Sunday. The trial results showed 94% lower levels of a genetically inherited heart disease risk factor in adults with elevated risk taking the highest test dose of the drug candidate.

The Hill on MSN · 2d

New drug cuts down genetically inherited heart disease risk factor

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, chief academic officer of the Heart, Vascular & Thoracic Institute at the Cleveland Clinic.

Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%

Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)],

1don MSN

Experts hail highly successful trial of Lilly's cholesterol-busting drug lepodisiran

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

BioPharma Dive3d

Lilly study data reinforce potential of new kind of heart drug

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...

3don MSN

Deadly cholesterol that doesn’t show up on routine tests is slashed by 94% with single dose of new drug

This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

Lepodisiran lowers Lp(a) substantially with infrequent administration

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

ACC25: Positive results with Lilly's Lp(a)-lowering drug

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results